Weatherford International's rise in ROCE and decrease in capital employed suggest enhanced efficiency in generating returns. The substantial total return over the past three years signals investors' anticipation of more positive future performance.
Weatherford International's high P/S ratio isn't justified given its below-industry projected revenue growth. The company's current price levels and not so promising growth outlook warrant investor caution. Future disappointment is possible if P/S falls to match the growth outlook.
Market Summary 15/8/2023 August kicked off with a noticeable 5% dip in the QQQ. However, a respite was observed, likely due to the$ARK Innovation ETF(ARKK.US)$ETF's continuous downfall in the last nine sessions, leading to a significant 17% drop this month. Such sharp declines are expected after robust growth periods, but it's concerning when they coincide with a trend switch to net lows. Even with today's market uplift, there was a rise in net lows for the Nasdaq an...
Weatherford国际股票讨论区
August kicked off with a noticeable 5% dip in the QQQ. However, a respite was observed, likely due to the $ARK Innovation ETF(ARKK.US)$ ETF's continuous downfall in the last nine sessions, leading to a significant 17% drop this month. Such sharp declines are expected after robust growth periods, but it's concerning when they coincide with a trend switch to net lows. Even with today's market uplift, there was a rise in net lows for the Nasdaq an...
2022前三季度营收增长16.5%,营业利润增长3倍到2.7亿,但由于高昂的利息费用和非核心费用,扣税后净利润为亏损0.25亿,少数股东又拿走0.21亿,最后普通股股民承担0.46亿的亏损。
目前看不到投资价值。
• $DBV Technologies(DBVT.US)$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics(ALDX.US)$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $美第奇新星生物技术(MNOV.US)$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid(CURV.US)$ +11% (In reaction to earnings/guidance)
• $诺瓦瓦克斯医药(NVAX.US)$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
• $Seres Therapeutics(MCRB.US)$ : Jefferies Upgrades to Buy from Hold
• $法拉利(RACE.US)$ : Kepler Upgrades to Hold from Reduce
Downgrades
• $Dutch Bros(BROS.US)$ : JPMorgan Downgrades to Neutral from Overweight - PT $40
• $Canopy Growth(CGC.US)$ : BMO Capital Downgrades to Underperform from Market Perform - PT Cdn$2.50 (from Cdn$6)
• $Cazoo(CZOO.US)$ : Citigroup Downgrades to Neutral from Buy - PT $1.50 (from $9)
• $查特工业(GTLS.US)$ : Barcla...
暂无评论